Showing 2281-2290 of 5957 results for "".
- The Alliance for Healthcare from the Eye Launches to Transform Disease Detectionhttps://modernod.com/news/the-alliance-for-healthcare-from-the-eye-launches-to-transform-disease-detection/2482801/A coalition of healthcare leaders announced the launch of the 'Alliance for Healthcare from the Eye (AHE)' at the Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City. AHE is a cross-sector initiative
- Hoya Vision Care Presents New Data on Myopia Management Spectacle Lenses at ARVOhttps://modernod.com/news/hoya-vision-care-presents-new-data-on-myopia-management-spectacle-lenses-at-arvo/2482800/Hoya Vision Care announced new clinical evidence from three key clinical studies highlighting the impact of 'Defocus Incorporated Multiple Segments (DIMS)' technology. The results were presented as part of the company’s 2025 scientific program, 'Exploring New Frontiers in Myopia
- Cognition Therapeutics Reports Topline Results Showing Oral Zervimesine Reduced Lesion Growth in Phase 2 Study in GAhttps://modernod.com/news/cognition-therapeutics-reports-topline-results-showing-oral-zervimesine-reduced-lesion-growth-in-phase-2-study-in-ga/2482793/Cognition Therapeutics reported topline results from the Phase 2 COG2201 ‘MAGNIFY’ trial of zervimesine (CT1812) in adults with geographic atrophy (GA). The results show zervimesine-treated participants had 28.6% slower GA lesion growth on average and at 18 months, and their lesi
- Kiora Pharmaceuticals Presents In Data Demonstrating the Potential of KIO-104 to Treat Proliferative Vitreoretinopathyhttps://modernod.com/news/kiora-pharmaceuticals-presents-in-data-demonstrating-the-potential-of-kio-104-to-treat-proliferative-vitreoretinopathy/2482784/Kiora Pharmaceuticals announced the results from a preclinical study demonstrating KIO-104 significantly reduced scar formation in an established in vivo model of proliferative vitreoretinopathy (PVR). The presentation, titled, "KIO-104, a novel small molecule inhibitor o
- 4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DMEhttps://modernod.com/news/4dmt-announces-rmat-designation-granted-by-fda-for-4d-150-for-dme/2482776/4D Molecular Therapeutics announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to 4D-150 for the treatment of diabetic macular edema (DME). RMAT designation is part of the 21st Century Cures Act and was created to expedite the developmen
- RetinAI and FVS Announce CE-MDR Certification for Co-Developed AI-Based DR Screening Algorithm, LuxIAhttps://modernod.com/news/retinai-and-fvs-announce-ce-mdr-certification-for-co-developed-ai-based-dr-screening-algorithm-luxia/2482773/RetinAI US and Fundación Ver Salud (FVS) have jointly announced that LuxIA, their co-developed AI algorithm for diabetic retinopathy (DR) screening, has successfully received CE-MDR certification as a Class IIb medical device under the European
- SpyGlass Pharma Presents 18-Month Data Demonstrating Improvements in Visual Acuity with IOL-Mounted Drug Delivery Platformhttps://modernod.com/news/spyglass-pharma-presents-18-month-data-demonstrating-improvements-in-visual-acuity-with-iol-mounted-drug-delivery-platform/2482772/SpyGlass Pharma announced that 18-month data from the first-in-human study of the SpyGlass Drug Delivery Platform demonstrated improvements in both visual acuity and IOP outcomes, key objectives for long-term treatment of glaucoma or ocular hypertension. Th
- Azalea Vision Raises €9 Million to Further Develop Intelligent Connected Vision Platformhttps://modernod.com/news/azalea-vision-raises-eur9-million-to-further-develop-intelligent-connected-vision-platform/2482765/Startup biotech company Azalea Vision announced the first closing of its €15 million Series A funding round, raising €9 million. In addition, the company announced that Robert J. Dempsey has been appointed Chairman of the Board to guide strategic growth in the European an
- Aurion Makes Leadership Announcementshttps://modernod.com/news/aurion-makes-leadership-announcements/2482757/Aurion Biotech announced the appointments of Edward J. Holland, MD, as Chief Medical Officer, and Eris P. Jordan, OD, as Chief Development Officer. Aurion is developing AURN001, an investigational, single-administration, allogeneic cell therapy for the treatment of corneal edema seconda
- FDA Denies Regeneron's BLA for Extended Dosing Intervals for Eylea HDhttps://modernod.com/news/fda-denies-regenerons-bla-for-extended-dosing-intervals-for-eylea-hd/2482747/Regeneron announced that the FDA has issued a complete response letter (CRL) regarding the supplemental Biologics License Application (sBLA) for the addition of extended dosing intervals (up to every 24 weeks) for Eylea HD (aflibercept) Injection 8 mg across all approved indication